Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Everolimus

FDA-approved product (tablet, oral), marketed as Afinitor, Afinitor Disperz, Everolimus and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Everolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenoma sebaceum
  • Anaplastic astrocytoma
  • Angiomyolipoma
  • Astrocytoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Clear cell renal carcinoma
  • Hamartoma
  • Kidney Angiomyolipoma
  • Neoplasm
  • Neuroendocrine neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Pancreatic neuroendocrine tumor
  • and 5 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor; mTOR Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Everolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Everolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

    NCT00634920 · start 2008-03

    Registered record
    Registry ID
    NCT00634920
    Conditions
    Renal Function
    Interventions
    everolimus; cyclosporine A; Enteric Coated Mycophenolate Sodium (EC-MPS); corticosteroids; Basiliximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-03
    Completion
    2013-05
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Function
    Interventioneverolimus; cyclosporine A; Enteric Coated Mycophenolate Sodium (EC-MPS); corticosteroids +1 more
    PhasePhase 4
    Registry statusCompleted

  • Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients

    NCT00457119 · start 2007-02

    Registered record
    Registry ID
    NCT00457119
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    RAD001
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-02
    Completion
    2009-11
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionRAD001
    PhasePhase 1
    Registry statusCompleted

  • Comparison of Biodegradable Polymer vs Durable-polymer in Diabetic Patients

    NCT02854423 · start 2007-01

    Registered record
    Registry ID
    NCT02854423
    Conditions
    Percutaneous Coronary Intervention; Diabetes Mellitus
    Interventions
    percutaneous coronary interventions
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-01
    Completion
    2016-01
    Enrolment
    1,347

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPercutaneous Coronary Intervention; Diabetes Mellitus
    Interventionpercutaneous coronary interventions
    PhaseNot recorded
    Registry statusCompleted

  • S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

    NCT00352443 · start 2006-09

    Registered record
    Registry ID
    NCT00352443
    Conditions
    Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    everolimus; lapatinib ditosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-09
    Completion
    2013-09
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Unspecified Adult Solid Tumor, Protocol Specific
    Interventioneverolimus; lapatinib ditosylate
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

    NCT00154310 · start 2005-06

    Registered record
    Registry ID
    NCT00154310
    Conditions
    Renal Transplantation
    Interventions
    Everolimus; Cyclosporine; Enteric-coated mycophenolate sodium; Corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-06
    Completion
    2008-09
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Transplantation
    InterventionEverolimus; Cyclosporine; Enteric-coated mycophenolate sodium; Corticosteroids
    PhasePhase 4
    Registry statusCompleted